Simcere Pharmaceutical's (HKG:2096) attributable profit is seen to jump 0.4% to 4.6% to between 718 million yuan and 748 million yuan in 2024 from 715 million yuan in 2023, according to a Friday filing with the Hong Kong Stock Exchange.
Revenue is also forecast to inch up 0.2% to 0.6% to between 6.62 billion yuan and 6.65 billion yuan.
The drug company plans to release fiscal 2024 results in late March.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.